Immunogenicity, safety, and predictors of response after a pneumococcal conjugate and pneumococcal polysaccharide vaccine series in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy.

@article{Abzug2006ImmunogenicitySA,
  title={Immunogenicity, safety, and predictors of response after a pneumococcal conjugate and pneumococcal polysaccharide vaccine series in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy.},
  author={Mark J. Abzug and Stephen Ira Pelton and Lin-Ye Song and Terence Fenton and Myron J. Levin and Sharon A. Nachman and William Borkowsky and Howard M. Rosenblatt and John F Marcinak and Arry Dieudonne and Elaine J. Abrams and Indu Pathak},
  journal={The Pediatric infectious disease journal},
  year={2006},
  volume={25 10},
  pages={920-9}
}
BACKGROUND The immunogenicity and safety of 2 doses of pneumococcal conjugate vaccine (PCV) and 1 dose of pneumococcal polysaccharide vaccine (PPV) were evaluated in human immunodeficiency virus (HIV)-infected children receiving highly active antiretroviral therapy (HAART). METHODS Children 2 to <19 years, receiving stable HAART for > or =3-6 months, with HIV RNA PCR <30,000-60,000 copies/mL, received 2 doses of PCV and 1 dose of PPV at sequential 8-week intervals. Antibodies to pneumococcal… CONTINUE READING
32 Extracted Citations
0 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 32 extracted citations

Similar Papers

Loading similar papers…